Avalo Therapeutics Inc AVTX 深 滬
已收盤 02-06 16:00:00 美东时间
14.19
+1.040
+7.91%
華盛通- 最 高14.45
- 今 開13.50
- 成交量 31.94万股
- 最 低 13.19
- 昨 收 13.15
- 總市值 1137.48万
- 52周最高 20.7199
- 市盈率 靜 --
- 換手率 39.84%
- 52周最低 3.39
- 委 比 -92.31%
- 總股本 80.16万
- 歷史最高 22032.00
- 量 比 0.63
- 振 幅 9.58%
- 歷史最低 3.39
- 每 手 1
- 風險率 5.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Guggenheim Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $50
Guggenheim analyst Yatin Suneja initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $50.
02-02 22:23
美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
HC Wainwright & Co. Reiterates Buy on Avalo Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Avalo Therapeutics (NASDAQ:AVTX) with a Buy and maintains $25 price target.
01-15 20:14
Avalo Therapeutics Files For Mixed Shelf Of Up To $750M
$750,000,000 ofCommon StockPreferred StockDebt SecuritiesWarrants and/orUnitsFrom time to time, we may offer up to $750,000,000 of any combination of the securities described in this prospectus in one or more offerings.
01-09 05:03
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Mizuho Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $39
Mizuho analyst Joseph Catanzaro initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $39.
2025-12-18 17:39
Avalo Therapeutics Q3 EPS $(2.19) Misses $(1.61) Estimate
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(2.19) per share which missed the analyst consensus estimate of $(1.61) by 35.6 percent. This is a 22.61 percent increase over losses of $(2.83) per share
2025-11-06 20:16
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Avalo Therapeutics announced the completion of enrollment in its Phase 2 LOTUS trial for AVTX-009 in adults with hidradenitis suppurativa (HS), enrolling approximately 250 patients, exceeding the target of 222. AVTX-009 is a high-affinity IL-1β inhibitor, and the trial aims to evaluate its efficacy, safety, and tolerability in reducing HS symptoms. The primary endpoint is achieving HiSCR75 at Week 16. The trial's success reflects the significant ...
2025-10-29 11:00
Avalo Therapeutics Highlights AVTX-009 Potential in New Presentation
Avalo Therapeutics ( ($AVTX) ) has shared an update. On October 10, 2025, Avalo...
2025-10-10 19:28
